Cure8 research brief
The study suggests that serum zinc by itself may not be a reliable indicator of endoscopic inflammation in UC; nutritional status and inflammation (for example albumin and CRP) can confound zinc levels.
Clinicians treating ulcerative colitis; researchers of IBD biomarkers; patients tracking micronutrient status
This single-center retrospective study compared serum zinc measurements taken within 30 days of colonoscopy to the UCEIS in 40 patients (44 pairs). In univariate analysis there was a weak, non-significant negative correlation between zinc and UCEIS.
In multivariable models adjusted for age, sex, disease extent, serum albumin, CRP, and advanced therapy, serum zinc was not independently associated with UCEIS. When albumin was removed from the model, zinc did show a statistically significant association, suggesting nutritional and inflammatory status influence zinc levels.
Practical takeaway: serum zinc alone did not reliably reflect endoscopic disease severity in this cohort; clinicians should consider albumin and inflammatory markers when interpreting zinc results.
Single-center retrospective design and small sample size limit generalizability. The provided content is based on the article abstract rather than full peer-reviewed supplementary data.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Vitamin D deficiency was common among Albanian patients with IBD and showed a weak inverse association with disease activity in ulcerative colitis, suggesting vitamin D status may relate to symptom burden or...
Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this...
